Autopsy report · NCT00869856

Study to Evaluate the Efficacy, Safety and Immunogenicity of Subcutaneous HX575 in the Treatment of Anemia Associated With Chronic Kidney Disease (SWEEP)

“investigation of adverse events in a related clinical study”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 3

Sponsor

Sandoz

Sponsor type

Industry

Conditions

Anemia; Chronic Renal Insufficiency

Interventions

HX575 solution for s.c. administration

Participants

0

Sites

19

Countries

Bulgaria, France, Germany, Romania, Spain

Trials that died the same way

• Safety and Bioactivity of AXT107 in Subjects With Diabetic Macular Edema
  “Adverse Events” (85% match in meaning)
• Short Versus Long Interval to Ileostomy Reversal After Ileal Pouch Surgery
  “Adverse Event” (80% match in meaning)
• Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia
  “Other - Adverse Events” (80% match in meaning)
• Ipilimumab + Androgen Depravation Therapy in Prostate Cancer
  “Due to adverse events” (78% match in meaning)
• "Watch and Wait" After Neo-adjuvant Chemoradiotherapy for Primary Locally Advanced Rectal Cancer.
  “Suspicion of adverse events” (76% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.